LabrulezLCMS-EN

💊 New way to track metformin adherence in type 2 diabetes—straight from blood! 🔬

• What’s new: Untargeted metabolomics/lipidomics revealed N‑lactoyl‑amino acids (e.g., N‑lactoyl‑phenylalanine) as dose‑responsive plasma biomarkers of metformin exposure 🩸
• Why it matters: Objective, ultra‑sensitive (nanomolar) “fingerprint” that distinguishes regular vs. irregular use; levels rise up to 7.2× in high‑exposure patients 🎯
• How it was done: 637 metformin‑treated patients + 143 controls; 614 metabolites annotated; strong correlations with metformin (ρ = 0.42–0.55) 📈
• Extra insights: T2D shows elevated lactate, organic acids, BCAAs; lipid remodeling with more saturated TAGs/DAGs and fewer cholesteryl esters, sphingomyelins, phospholipids 🧬
• Who’s behind it: Tomáš Čajka, Laboratory of Translational Metabolism, Institute of Physiology CAS, with the Institute for Clinical and Experimental Medicine in Prague and the West Coast Metabolomics Center (University of California, Davis) 🤝
• Read more: Clin Pharmacol Ther 119:1057–1069 🔗 https://doi.org/10.1002/cpt.70205

New Biomarkers Track Metformin Adherence in Diabetes Advanced metabolomics revealed new plasma biomarkers that accurately monitor metformin adherence and metabolic response in type 2 diabetes patients.